anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The world is confronting Coronavirus Disease-2019 (COVID-19) pandemic caused by SARS-CoV-2 virus, which is causing many deaths and burden on intensive care facilities. Data regarding epidemiologic characteristics in children and young adults is limited, especially in the context of educational settings. Due to mild symptoms or even asymptomatic cases in children, the rate of SARS-CoV-2 infected children is underestimated. Therefore, the present study aims to determine the incidence of SARS-CoV-2 infection in children at 3 timepoints during 12 months expressed as seroconversion measured in non-invasive saliva sampling in Tübingen, a defined study area. Children and adolescents (N = 1850) in the age of 1 to 17 years will be recruited via child-care, kindergarten and primary and secondary schools and followed-up for 12 months: shortly after release of lock-down measures in summer 2020, before winter and after the winter. An adult cohort (adult comparator group) is sampled at the same time points for incidence comparisons. To validate the ELISA for SARS-CoV-2 antibody measurements in saliva compared to blood, and to understand the half-life of SARS-CoV-2 antibodies in respective body fluids, peripheral blood and in saliva will be sampled every 2 months in an additional adult group (adult validation group).
A system and a method for determining an assessed carbohydrate to insulin ratio of a patient is described. The system and the method can comprise a memory component adapted for storing an initial set of values comprising at least one of a blood glucose level, a target blood glucose level, an insulin sensitivity, and, an estimated carbohydrate to insulin ratio. The system and the method can also comprise a bolus selection component adapted for selecting a test bolus corresponding to the determined initial set of values and a planned meal. In one implementation, the bolus selection component can receive bolus dose input from a user. In another implementation, the bolus selection component can estimate the bolus dose using a set of available inputs (e.g. the amount of carbohydrates in the planned meal). The system and the method can further comprise a user interface component adapted for receiving a confirmation that the test bolus has been administered to the patient. In some implementations, the user interface component can be adapted for selecting a meal of a known content.
PURPOSE: Some studies have found that the pathological formation of kidney stones is closely related to injury and inflammatory response. Behaviors such as dietary composition, physical activity, obesity and smoking can all affect the body's oxidative stress levels. In order to evaluate the effects of various diets and lifestyles on the body's oxidative and antioxidant systems, an oxidative balance score was developed. To investigate whether the OBS is associated with the development of kidney stones.
METHODS: Data were taken from the National Health and Nutrition Examination Survey (NHANES) from 2007-2018, followed by retrospective observational studies. The association between kidney stones and OBS was analyzed using survey-weighted logistic regression by adjusting for demographics, laboratory tests, and medical comorbidity covariates. The oxidative balance score is calculated by screening 16 nutrients and 4 lifestyle factors, including 5 prooxidants and 15 antioxidants, based on prior information about the relationship between oxidation levels in the body and nutrients or lifestyle factors.
RESULTS: A total of 26,786 adult participants were included in the study, of which 2,578, or 9.62%, had a history of nephrolithiasis. Weighted logistic regression analysis found an association between OBS and kidney stones. In the fully tuned model, i.e., model 3, the highest quartile array of OBS was associated with the lowest quartile array of OBS (OR = 0.73 (0.57, 0.92)) with the risk of kidney stone (p = 0.01), and was statistically significant and remained relatively stable in each model. At the same time, the trend test in the model is also statistically significant. With the increase of OBS, the OR value of kidney stones generally tends to decrease.
CONCLUSIONS: There is an inverse correlation between OBS and kidney stone disease. At the same time, higher OBS suggests that antioxidant exposure is greater than pro-oxidative exposure in diet and lifestyle, and is associated with a lower risk of kidney stones.
Chemotherapeutic agents are used to treat infections caused by bacteria, virus, protozoa, parasites, and various malignant diseases like cancer. The major problem associated with use of chemotherapeutic agents is resistance to chemoptherapeutic agents. The drugs restoring sensitivity of chemotherapeutic agents are broadly known as chemosensitizers. Compounds belonging to a group of R-1-3-benzodiaxole are found to be chemosensitizer as per the present invention. Piperine is one such compound belonging to R-1-2benzodiaxole group. It is found to reverse resistance to chemotherapeutic agents like rifampicin at a dose which is easily achievable after oral ingestion of the drug.
BACKGROUND: Cardiac catheterizations in horses are mainly performed in the right heart, as access to the left heart traditionally requires an arterial approach. Transseptal puncture (TSP) has been adapted for horses but data on follow-up and closure of the iatrogenic atrial septal defect (iASD) are lacking.
HYPOTHESIS/OBJECTIVES: To perform TSP and assess postoperative complications and iASD closure over a minimum of 4 weeks.
ANIMALS: Eleven healthy adult horses.
METHODS: Transseptal puncture was performed under general anesthesia. Serum cardiac troponin I concentrations were measured before and after puncture. Weekly, iASD closure was monitored using transthoracic and intracardiac echocardiography. Relationship between activated clotting time and anti-factor Xa activity during postoperative enoxaparin treatment was assessed in vitro and in vivo.
RESULTS: Transseptal puncture was successfully achieved in all horses within a median duration of 22 (range, 10-104) minutes. Balloon dilatation of the puncture site for sheath advancement was needed in 4 horses. Atrial arrhythmias occurred in 9/11 horses, including atrial premature depolarizations (N = 1), atrial tachycardia (N = 5), and fibrillation (N = 3). Serum cardiac troponin I concentrations increased after TSP, but remained under the reference value in 10/11 horses. Median time to iASD closure was 14 (1-35) days. Activated clotting time correlated with anti-factor Xa activity in vitro but not in vivo.
CONCLUSIONS AND CLINICAL IMPORTANCE: Transseptal puncture was successfully performed in all horses. The technique was safe and spontaneous iASD closure occurred in all horses. Clinical application of TSP will allow characterization and treatment of left-sided arrhythmias in horses.
A headache is the most significant complication of dural puncture during epidural placement. This complication leads to longer hospital stays and many repeated visits to hospital for management. Women suffering from severe postdural puncture headache (PDPH) are often bedridden and unable to care for themselves or their babies.The efficacy of epidural blood patch as a "gold standard" therapy is over-estimated by the earlier, poor quality studies. The prevalence of dural puncture during epidural anesthesia using current techniques ranges from 0.03 to 6% in the literature. Of these patients, 70 to 80% will suffer from moderate to severe PDPH. Avoidance of dural puncture is always the goal. However, complete avoidance is unlikely using current techniques of needle placement. This study proposes another method of prevention (i.e., reducing the gauge of the epidural needles if it is shown to be suitable for continuous infusion in adults). Most of the risk factors for developing PDPH cannot be changed (e.g., younger age, female sex, low body mass index, history of migraines). However, epidural needle gauge is a modifiable risk factor. Evidence suggests that the use of smaller gauge epidural needles, like spinal needles, have the potential to reduce the incidence and severity of PDPH.
The invention discloses a weight-reducing spray and the application method. The raw materials adopted for the invention contain Pericarpium Citri Reticulatae, Rhizoma Pinelliae, Poria, Radix Glycyrrhizae, Radix Aucklandiae, Rhizoma Atractylodis, Rhizoma Atractylodis Macrocephalae, Rhizoma Cyperi, Rhizoma Chuanxiong and Radix Angelicae Sinensis. The weight proportion of the raw materials are that  Pericarpium Citri Reticulatae : Rhizoma Pinelliae : Poria : Radix Glycyrrhizae : Radix Aucklandiae : Rhizoma Atractylodis : Rhizoma Atractylodis Macrocephalae : Rhizoma Cyperi : Rhizoma Chuanxiong : Radix Angelicae Sinensis equals to 1:1:1.5:0.6:1:1:1:0.9:0.9:1.2. The raw materials are crushed into rough powder, filtered, mixed with ethanol, infused in the ethanol and filtered again; the residues are compressed, the filtered liquid and the compressed liquid are mixed, statically placed, filtered, combined with distilled water and bottled. When in use, the medicine of the spray is directly sprayed at the point cv 8 (the navel), the effective ingredients of the medicine are directly flowed into the channels of the human body and the drug utilization ratio is improved to the utmost extent. The invention has the advantages of evident effect, no need of diet, permanent drug potency, safety and no side effects.
BACKGROUND: Patients with migraine are vulnerable to insufficient sleep, but the impact of sleep restriction is largely unknown. In addition, the importance of sleep may be different in patients with migraine who mostly have attack onsets during sleep, so called sleep-related migraine, compared to patients with non-sleep-related migraine. In this study we investigate the effect of sleep restriction on endogenous pain modulation in patients with migraine and healthy controls. We also compared the effect of sleep restriction in sleep-related and in non-sleep-related migraine.
METHODS: Measurements were conducted in 39 patients with migraine between attacks and 31 controls, once after habitual sleep and once after two consecutive nights of partial sleep restriction. There were 29 and 10 patients with non-sleep-related and sleep-related migraine respectively. Test stimulus was 2-min tonic noxious heat to the left volar forearm. Temporal summation was calculated as the regression coefficient for rated pain in the late part of this 2-min stimulation. Conditioning stimulus was right hand-immersion in 7 °C water. Conditioned pain modulation was defined as the difference in rated pain with and without the conditioning stimulus and was calculated for temporal summation and mean rated pain for the test stimulus. The effect of sleep restriction on temporal summation and conditioned pain modulation was compared in migraine subjects and controls using two-level models with recordings nested in subjects.
RESULTS: Conditioned pain modulation for temporal summation of heat pain tended to be reduced after sleep restriction in patients with migraine compared to controls (p = 0.060) and, in an exploratory analysis, was reduced more after sleep restriction in sleep-related than in non-sleep-related migraine (p = 0.017). No other differences between groups after sleep restriction were found for temporal summation or conditioned pain modulation.
CONCLUSION: Patients with migraine may have a subtly altered endogenous pain modulation system. Sleep restriction may have an increased pronociceptive effect on this system, suggesting a mechanism for vulnerability to insufficient sleep in migraine. This effect seems to be larger in sleep-related migraine than in non-sleep-related migraine.
Neuroinflammation, marked by the release of proinflammatory cytokines and resulting neuronal death, is a multifaceted process extending beyond traditional inflammatory pathways. Microglia, primary cells in the inflammatory response, rapidly activate during neuroinflammation and produce proinflammatory and cytotoxic factors that affect neuronal function. Recent evidence highlights the significant role of abnormal lipid droplet (LD) deposition in the pathogenesis of neuroinflammation. While microglia are known to influence LD aggregation during neuroinflammation, the regulatory mechanism within neurons is not well understood. Our study demonstrates that lipopolysaccharide-activated microglia induce the accumulation of LD in neurons, identifying microglial-derived lactic acid as a key mediator in this process. Excessive lipid accumulation threatens neuronal function, a phenomenon reversed by eliminating microglia. Our study demonstrates that lipopolysaccharide-activated microglia induce the accumulation of LD in neurons, identifying microglial-derived lactic acid as a key mediator in this process. Excessive lipid accumulation threatens neuronal function, a phenomenon reversed by eliminating microglia.
Ciprofloxacin is indicated in pediatric patients (less than 18 years of age) only for cUTI, prevention of inhalational anthrax (post exposure), and plague [see Indications and Usage (Error! Hyperlink reference not valid., Error! Hyperlink reference not valid., Error! Hyperlink reference not valid.)]. An increased incidence of adverse reactions compared to controls, including reactions related to joints and/or surrounding tissues, has been observed [see Adverse Reactions (6.1)].

In pre-clinical studies, oral administration of ciprofloxacin caused lameness in immature dogs. Histopathological examination of the weight-bearing joints of these dogs revealed permanent lesions of the cartilage. Related quinolone-class drugs also produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species [see Use in Specific Populations (8.4) and Nonclinical Toxicology (13.2)].
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an inhibitor of MET kinase signaling (e.g. a small molecule MET kinase inhibitor, an anti-MET antibody, or an HGF binding protein) and an inhibitor of IGF-1R signaling (e.g. a small molecule IGF-1R kinase inhibitor (e.g. OSI-906), an anti-IGF-1R antibody, or one or more IGF binding proteins (e.g. IGFBP3)). The present invention also provides a pharmaceutical composition comprising a combination of an inhibitor of MET kinase signaling and an inhibitor of IGF-1R signaling, with a pharmaceutically acceptable carrier. The present invention also provides such methods or compositions where the inhibitory activities of MET kinase signaling and IGF-1R kinase signaling reside in the same molecule.
PURPOSE: An image processing device, a control method thereof, and a computer-readable storage medium are provided to transmit a used cross-sectional image first to change the order of transmitting cross-sectional images, thereby shortening waiting time. CONSTITUTION: An image server(3) comprises the following steps. A CPU(301) performs various processing by a control program stored in a ROM or a RAM. A storage unit(304) stores a cross-sectional group, a location list, and transmission order information. An interface(305) connects the image server with a network(2). A cross-sectional image is displayed on a display unit(406).
Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, received the US Food and Drug Administration approval in 2022 for second-line treatment of diffuse large B-cell lymphoma (DLBCL) for patients with refractory disease or early relapse after first-line chemoimmunotherapy. This decision was based on the TRANSFORM study demonstrating improvements in event-free survival with liso-cel compared with standard care. Given the high costs of CAR T-cell therapies, particularly as they transition to second-line treatment, a cost-effectiveness analysis is essential to determine their economic viability. The study used a partitioned survival model with standard parametric functions to evaluate the cost-effectiveness of liso-cel aganist platinum-based chemotherapy followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation over a lifetime horizon The analysis relied on data from the TRANSFORM and TRANSCEND trials, established literature, and public data sets to calculate the incremental cost-effectiveness ratio (ICER). For a representative cohort of US adults aged 60 years, ICER of liso-cel was $99 669 per quality-adjusted life-year (QALY) from a health care sector perspective and $68 212 per QALY from a societal perspective, confirming its cost-effectiveness at the $100 000 per QALY threshold. Nonetheless, under certain scenarios, liso-cel surpasses this benchmark but remains within the US acceptable range of $150 000 per QALY. A key finding underlines the importance of incorporating productivity losses into such analyses to capture the broader societal values of novel therapies. Although these therapies offer substantial clinical benefits, their high acquisition costs and limited long-term data critically challenge their economic sustainability.
Plaque index, gingival index, bleeding on probing index, probing pocket depth and clinical attachment levels were measured from 6 sites of each tooth to evaluate the periodontal status of the patients. Panoramic radiographs were taken from all patients. Vertical/horizontal bone loss on the radiographs was evaluated to determine the stage and grade of periodontitis. Gingival crevicular fluid samples were collected from the 5 periodontal pockets with the deepest PPD before and 3 months after treatment. Eppendorf tubes were stored at -80°C. Non-surgical periodontal treatments were started under local anesthesia. Oral hygiene education was given to each patient after treatment. Modified Bass technique was explained as a brushing technique. Interdental cleaning was explained. The patient was told not to use any chemical agent for plaque removal. 3 months after the treatment gingival crevicular fluid samples are collected and clinical examination parameters were measured again.
1. A pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, characterized in that comprises an amount of fenofibrate higher or equal to 60 wt.%. 2. The composition according to claim 1, characterized in that binding cellulose derivative, as solubilizing adjuvant is hydroxypropylmethylcellulose. 3. The composition according to claim 2, characterized in that hydroxypropylmethylcellulose has an apparent viscosity 2.4 to 18 cP, preferably 2.4 to 3.6 cP. 4. The composition according to any one of claims 1 to 3, characterized in that comprises fenofibrate higher or equal to 70 wt.%, more preferably higher or equal to 75 wt.% relative to the mass composition. 5. The composition according to any one of claims 1 to 4, characterized in that the surfactant is selected from the group consisting of polyoxyethylene-20-monooleatsorbate, monolauratsorbate and sodium laurylsulfate. 6. The composition according to any one of claims 1 to 5, characterized in that the surfactant comprises 1 to 10 wt.%, preferably 3 to 5 wt.% relative to the fenofibrate mass. 7. The composition according to any one of claims 2 to 6, characterized in that the mass ratio fenofibrate/ hydroxypropylmethylcellulose (HPMC) is from 5/1 to 15/1. 8. The composition according to any one of claims 1 to 7, characterized in that binding cellulose derivative comprises 2 to 15 wt.%, preferably 5 to 12 wt.% relative to the composition mass. 9. The composition according to any one of claims 1 to 8, characterized in that comprises at least one excipient, such as diluent, in particular, lactose, anti-frothing agent, in particular, dimethylpolyoxsane, or polymethylsiloxane and dioxide silicon, or a lubricant, in particular, talc. 10. The composition according to any one of claims 1 to 9, characterized in that average fenofibrate particles size is below 15 mum, preferably below 8 mum. 11. The composition according to any one of claims 1 to 10, characterized in that preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables to enhance the bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent. 12. Process of preparing of composition according to any of claims 1-11, characterized in that the granules are prepared by applying on neutral microgranules by means of pulverization of aqueous suspension containing surfactant, solubilized cellulose derivative as binding and micronized fenofibrate in suspension. 13. Process of preparation of composition according to any of claims 1-11, characterized in that the granules are prepared by granulation of powder by wet method, according to which the components of the powder, in particular micronized fenofibrate, surfactant and cellulose derivative are granulated by wet method using an aqueous softening solution, then the granules are dried and calibrated.
Subjects are treated with single dose lithium first. Then after at least 7 day washout, the subjects start PD 0332334 treatment from day 1 to day 9. At day 4 of PD 0332334 treatment, single dose lithium is given to subjects.
Ursodiol tablets, USP 250 mg is available as a film-coated tablet for oral administration. Ursodiol tablets, USP 500 mg is available as a scored film-coated tablet for oral administration. 

Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring bile acid found in small quantities in normal human bile and in larger quantities in the biles of certain species of bears. It is a bitter-tasting white or almost white powder consisting of crystalline particles freely soluble in alcohol and glacial acetic acid, sparingly soluble in chloroform, slightly soluble in ether, acetone, methylene chloride and practically insoluble in water. The chemical name of ursodiol is 3α,7β-dihydroxy-5β-cholan-24-oic (C24H40O4). Ursodiol has a molecular weight of 392.56. Its structure is shown below.

Inactive ingredients: Sodium Starch Glycolate, Povidone, Sodium Lauryl Sulfate, Tromethamine, Microcrystalline Cellulose, Polyethylene Glycol 3350, Magnesium Stearate, Opadry Clear YS-1-7006, Hypromellose, Macrogol/PEG 400, Macrogol/PEG 8000, Purified Water.
Participants will receive a commercially available 6-week, online media-rich course of CBT-I delivered by an animated "virtual therapist" (Sleepio). Treatment content of this intervention includes behavioural components (sleep restriction, stimulus control, and relaxation), cognitive components (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, and 'putting the day to rest') and educational components (psychoeducation and sleep hygiene). Each of the 6 sessions lasts \~ 30 minutes and incorporates an initial progress review in relation to individualised goals, and exploration of self-reported diary data relating to the participant's current sleep status and pattern. The full program can be accessed via a website or iOS app. Participants will have access to the intervention for up to 12 weeks.